Patupilone (Epothilone B)

For research use only.

Catalog No.S1364 Synonyms: EPO906

8 publications

Patupilone (Epothilone B) Chemical Structure

Molecular Weight(MW): 507.68

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 250 In stock
USD 57 In stock
USD 70 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Patupilone (Epothilone B) has been cited by 8 publications

4 Customer Reviews

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9. Patupilone (Epothilone B) purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell NIWx[m1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3zocGlvcGmkaYTpc44hd2ZiaIXtZY4hVENvMj3h[EBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzenLUC2JO69VQ>? M3f6THNCVkeHUh?=
human A431 cell M{WwPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml7RTY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OT64OoUuODZizszN NHTVWWVUSU6JRWK=
human SW1710 cell NVn6SWh4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYXJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVRmNTB3IN88US=> M2fmRnNCVkeHUh?=
human Daoy cell NFT2dHBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXq1dlIzUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0zNjd|ZT2wOUDPxE1? Ml3DV2FPT0WU
human BFTC-905 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3DSmp2UW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOUnlMVA2KM7:TR?= M17mT3NCVkeHUh?=
human A375 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13ZT2wOUDPxE1? MknVV2FPT0WU
human RKO cell NFfReIVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIDUZnZKdmirYnn0bY9vKG:oIHj1cYFvKFKNTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOFdmNTB3IN88US=> NUnzbIcxW0GQR1XS
human KYSE-510 cell M1f4Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NU\PXXR4UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVUyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwM{jlMVA2KM7:TR?= Moq2V2FPT0WU
human HLE cell NX;wZog5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX;oUYV1UW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlI3\S1yNTFOwG0> MmDzV2FPT0WU
human MCF7 cell M4XtVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHzPPW1KdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY3\S1yNTFOwG0> MUTTRW5ITVJ?
human 786-0 cell M33IcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWXJN4ZyUW6qaXLpeIlwdiCxZjDoeY1idiB5OE[tNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTFibl2= M1TCOnNCVkeHUh?=
human TE-8 cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXPJcohq[mm2aX;uJI9nKGi3bXHuJHRGNThiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxNUBvVQ>? MUTTRW5ITVJ?
ovarian carcinoma 1A9 cell M{\nc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCxdnHybYFvKGOjcnPpco9u[SBzQUmgZ4VtdCCpcn;3eIg> MX[xOlE{PDl{OB?=
human PANC-03-27 cell NHn2cnJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3XLcGlvcGmkaYTpc44hd2ZiaIXtZY4hWEGQQz2wN{0zPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUOyJO69VQ>? MWTTRW5ITVJ?
human VMRC-RCZ cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NETYcnhKdmirYnn0bY9vKG:oIHj1cYFvKF[PUlOtVmNbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zM{[g{txO MknqV2FPT0WU
human IGROV-1 cell M3zaO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXvrfXppUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNU[g{txO MVzTRW5ITVJ?
human MG-63 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo\2TY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVY2KM7:TR?= MVLTRW5ITVJ?
human SIG-M5 cell NFzyd3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIq4OlVKdmirYnn0bY9vKG:oIHj1cYFvKFOLRz3NOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTZ7IN88US=> NXXpdHV2W0GQR1XS
human NCI-H650 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3zYU2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5IN88US=> MVPTRW5ITVJ?
human PSN1 cell NGnYUIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmfwTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xO|Mh|ryP MW\TRW5ITVJ?
human PA-1 cell Ml36S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYHSdFIyUW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzRizszN NUK1SI9mW0GQR1XS
KB-8511 cells NX\ReZVxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFnnOog4OiCq Ml;WR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IITo[UBoem:5dHigc4YheGGlbHn0ZZhmdC2{ZYPpd5RidnRiaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscJMhU0JvOEWxNUBjgSB3MDDw[ZJk\W62IDi3NkBpeiCneIDvd5Vz\SluIFnDOVA:OC5zODFOwG0> M{nFdlEyOTN|MEi2
KB-31 cells M1f4ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmLOO|IhcA>? M2fMbGNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDD0bIUh\3Kxd4ToJI9nKHCjY3zpeIF5\Wxvc3Xud4l1cX[nIHj1cYFvKGWyaXTldo1wcWRiY3HyZ4lvd22jIHPlcIx{KEuELUOxJIJ6KDVyIIDldoNmdnRiKEeyJIhzKGW6cH;zeZJmMQ>? M1LpSVEyOTN|MEi2
human BHY cell MkD1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkntTY5pcWKrdHnvckBw\iCqdX3hckBDUFliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG5OUBvVQ>? M4n6ZnNCVkeHUh?=
human BB30-HNC cell NIDlRodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1fBZWlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJyMTFOwG0> M4CxPXNCVkeHUh?=
human HOS cell NUHyeG1IT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{fQZ2lvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVUh|ryP NH3ScJhUSU6JRWK=
human 639-V cell NWnvWZJ2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHTKfoJKdmirYnn0bY9vKG:oIHj1cYFvKDZ|OT3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOThizszN MljSV2FPT0WU
human ES1 cell  MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIP1VINKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlIyKM7:TR?= MVvTRW5ITVJ?
human TE-15 cell  MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmfETY5pcWKrdHnvckBw\iCqdX3hckBVTS1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI2KM7:TR?= M2\rS3NCVkeHUh?=
human LXF-289 cell NUW4bJY4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFu0WpFKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ5NzFOwG0> MYHTRW5ITVJ?
human CAL-12T cell M2TKPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFzKRZZKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2xNnQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|OTFOwG0> NW\PWHR{W0GQR1XS
human T84 cell NX3lNGxGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFPQZoJKdmirYnn0bY9vKG:oIHj1cYFvKFR6NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlQh|ryP M4nicnNCVkeHUh?=
human KYSE-450 cell M3ewPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPTV4R3UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVQ2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMk[3JO69VQ>? M4e2b3NCVkeHUh?=
human LCLC-103H cell MoXZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWfJcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvMUCzTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzFibl2= MVHTRW5ITVJ?
human NCI-H810 cell MkX6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmPCTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{IN88US=> M1TDOnNCVkeHUh?=
human HUTU-80 cell MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NW\pVlQ2UW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|Mkig{txO MknWV2FPT0WU
human NCI-H460 cell NFn4VJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNE[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzNizszN Mlj2V2FPT0WU
human HGC-27 cell M13sNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3na[mlvcGmkaYTpc44hd2ZiaIXtZY4hUEeFLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzhizszN MVLTRW5ITVJ?
human HSC-2 cell NGDMXWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlfxTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|Y{KG6P MlXRV2FPT0WU
human IA-LM cell NUDKemlGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4DaR2lvcGmkaYTpc44hd2ZiaIXtZY4hUUFvTF2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM6OyEQvF2= NV3YOoJUW0GQR1XS
human HMV-II cell M{DZVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFzPcmdKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl2IN88US=> Mmi2V2FPT0WU
human COLO-679 cell NYX4NGhWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGHvfmVKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlc6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|OUSg{txO MmroV2FPT0WU
human NCI-H2122 cell NWn2[HY{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDFizszN MkfUV2FPT0WU
human CAL-39 cell NGmzem5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFEyKM7:TR?= MnjBV2FPT0WU
human SW954 cell NWL6[VVmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHG5UppKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OzZizszN M4XwT3NCVkeHUh?=
human LCLC-97TM1 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGxEVENvOUfUUVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjR2NDFOwG0> NGHuN3hUSU6JRWK=
human KYSE-270 cell MoCxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NES1XXpKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNlcxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52NEWg{txO MmfTV2FPT0WU
human NB13 cell NWfybmV3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnfJTY5pcWKrdHnvckBw\iCqdX3hckBPSjF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60OFch|ryP NHfI[mtUSU6JRWK=
human SK-LMS-1 cell M4XvR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2i4VGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTF3TMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjZ2NjFOwG0> M1HW[3NCVkeHUh?=
human SW620 cell Mn\US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXzOO|VwUW6qaXLpeIlwdiCxZjDoeY1idiCVV{[yNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR6IN88US=> MkXtV2FPT0WU
human HCT-15 cell NVXrN4pWT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFPH[YJKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzF5IN88US=> NV\oc4FTW0GQR1XS
human DU-145 cell NULpNVNnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MljWTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlczOSEQvF2= MkXzV2FPT0WU
human ST486 cell MoD3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEfYbnBKdmirYnn0bY9vKG:oIHj1cYFvKFOWNEi2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OjFizszN NHWySGhUSU6JRWK=
human A427 cell MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NELlfIdKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlgzQCEQvF2= MVvTRW5ITVJ?
human HT-1080 cell M2H0e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFTPR21KdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh2MjFOwG0> NEW0OWdUSU6JRWK=
human NCI-H2009 cell M1K4dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYrFXnNjUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxODliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLki2NkDPxE1? NULVcmtGW0GQR1XS
human SK-LU-1 cell M{\uT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnHoTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PjZizszN NUHzbIE6W0GQR1XS
human SCC-4 cell M2TSXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGHqNXhKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PzdizszN NI\4ZYpUSU6JRWK=
human NCI-H1299 cell MmHoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUK5PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDhizszN M4DhS3NCVkeHUh?=
human NH-12 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\XTY5pcWKrdHnvckBw\iCqdX3hckBPUC1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFkyKM7:TR?= NIDidlJUSU6JRWK=
human SK-UT-1 cell MmPwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVmzUGNwUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OUKg{txO Mn\TV2FPT0WU
human Bel7402 M4DkTnBzd2yrZnXyZZRqd25iYYPzZZk> NV\sT5NHPzJiaB?= Mkj3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwQVAvQSEQvF2= MVmyNlMzODN3NB?=
human A388 cell Mm\aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWLjVYhEUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PCEQvF2= MkexV2FPT0WU
human SW982 cell M3jMW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmrDTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVk6KM7:TR?= M1LLZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol

Kinase Assay:[1]
- Collapse

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
Cell Research:[2]
- Collapse
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage powder
in solvent
Synonyms EPO906
Smiles CC1CCCC2(C)OC2CC(OC(=O)CC(O)C(C)(C)C(=O)C(C)C1O)\C(C)=C\C3=CSC(=N3)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00496600 Completed Drug: Patupilone|Drug: RAD001 Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers The State University of New Jersey July 2007 Phase 1
NCT00442741 Withdrawn Drug: Patupilone|Drug: Patupilone + Omeprazole Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00468260 Terminated Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00426140 Completed Drug: Patupilone Advanced Malignancies|Solid Tumors Novartis Pharmaceuticals|Novartis August 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Patupilone (Epothilone B) | Patupilone (Epothilone B) supplier | purchase Patupilone (Epothilone B) | Patupilone (Epothilone B) cost | Patupilone (Epothilone B) manufacturer | order Patupilone (Epothilone B) | Patupilone (Epothilone B) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID